The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

Mergers & AcquisitionsMediumUpdated×3•Originally published 28 April 2026•Updated 28 April 2026•

1 min read

Gilead Sciences Finalizes $7.8 Billion Acquisition of Arcellx

Key Facts

1Gilead Sciences finalized its acquisition of Arcellx for approximately $7.8 billion to gain full control over the anito-cel therapy.

2The deal includes $115 per share in cash plus a $5 contingent value right tied to future sales of anito-cel.

about 1 month ago

Version History

Version 3about 1 month ago

What changed: The story was updated to include the specific closing date of April 28, 2026, and details regarding the acquisition of a 77.2% stake from institutional investors via a tender offer.

Version 2about 1 month ago

What changed: The story was updated to note that the anito-cel therapy is currently under regulatory review and to clarify that the projected 2028 earnings accretion is dependent on FDA approval.

Version 1about 1 month ago

What changed: The story was updated to include details regarding the integration of the therapy into the Kite Oncology unit and the elimination of future profit-sharing and royalty obligations.

Gilead Sciences finalized its acquisition of Arcellx on April 28, 2026, after completing the purchase of a 77.2% stake from investors including New Enterprise Associates and SR One Capital Management. The $7.8 billion deal was executed through a tender offer and subsequent merger, making Arcellx a wholly-owned subsidiary. This strategic move secures Gilead full control over the anito-cel therapy for multiple myeloma, which will be integrated into its Kite Oncology unit. The acquisition terms provided Arcellx shareholders with $115 per share in cash plus a $5 contingent value right (CVR). While the deal is expected to be accretive starting in 2028, this remains contingent upon receiving necessary FDA approval. This integration marks a pivotal step in Gilead's long-term strategy to expand its advanced oncology portfolio.